...
首页> 外文期刊>Histology and histopathology >Retrospective analysis of 25 immunohistochemical tissue markers for differentiating multilocular cystic renal neoplasm of low malignant potential and multicystic renal cell carcinoma
【24h】

Retrospective analysis of 25 immunohistochemical tissue markers for differentiating multilocular cystic renal neoplasm of low malignant potential and multicystic renal cell carcinoma

机译:对25例免疫组织组织标志物分化为低聚势和多性肾细胞癌多层囊性肾肿瘤的25例免疫组织组织标志物

获取原文
获取原文并翻译 | 示例
           

摘要

Multilocular cystic renal neoplasm of low malignant potential (MCRNLMP) and multicystic renal cell carcinoma (MCRCC) are morphologically indistinguishable. MCRNLMP is a tumor composed entirely of numerous cysts, the septa of which contain individual or groups of clear cells without expansile growth. However, unlike MCRCC, neither recurrence nor metastasis has been reported in MCRNLMP. The aim of this study was to identify significant differential pathological characteristics in resected specimens from patients diagnosed with MCRNLMP (n=13) and MCRCC (n=17) using immunohistochemistry of 25 tissue markers. Staining interpretation was performed semi-quantitatively using the H-score (0-300) or intensity score (0-3), and differences between groups were evaluated using the Fisher exact and Wilcoxon rank-sum tests. During a median follow-up of 66.2 months (1-141.9 months), there was only one case of MCRCC recurrence among all 30 patients, including 19 (63.3%) at stage pT1a, 8 (26.7%) at stage pT1b, and 3 (10.0%) patients at stage pT2. Tumor necrosis rate (0% vs. 52.9%) and median tumor size (3.2 cm vs. 4.1 cm) significantly differed between MCRNLMP and MCRCC samples. Among the 25 tissue markers, only HIF1a, PDGFR alpha, SMA, VEGFR1, VEGFR2, VEGFR3, CD10, CD31, CD34, CK7-tubule, TGAse-2, and Ki-67 showed significantly different expression between the groups. These tissue markers with differential expression between MCRNLMP and MCRCC can provide a clue to understanding their distinct pathophysiology.
机译:低恶性潜力(MCRN1MP)和多象性肾细胞癌(MCRCC)的多层囊性肾肿瘤在形态上难以区分。 MCRN1MP是一种完全由许多囊肿组成的肿瘤,其隔膜含有含有的单独或透明细胞的颗粒,而不会膨胀生长。然而,与MCRCC不同,MCRN1MP中没有报告复发性也不报告转移。本研究的目的是鉴定使用25种组织标记物的免疫组织化学诊断患有MCRN1MP(n = 13)和MCRCC(n = 17)的患者切除的患者的显着差异病理特征。使用H-Score(0-300)或强度评分(0-3)半定量进行染色解释,并使用Fisher精确和Wilcoxon秩-UM测试评估组之间的差异。在66.2个月(1-141.9个月)的中位随访期间,所有30名患者中只有一种MCRCC复发,包括阶段PT1A期间的19(63.3%),PT1B期,3例(26.7%),3例(10.0%)阶段PT2患者。肿瘤坏死率(0%vs.52.9%)和McRN1MP和MCRCC样品之间的肿瘤大小(3.2cm与4.1cm)显着差异。在25个组织标记中,仅HIF1A,PDGFRα,SMA,VEGFR1,VEGFR2,VEGFR3,CD10,CD31,CD34,CK7-小管,TGASE-2和KI-67在组之间显示出显着不同的表达。这些具有MCRN1MP和MCRCC之间的鉴别表达的组织标记可以提供有关理解其不同病理生理学的线索。

著录项

  • 来源
    《Histology and histopathology》 |2018年第6期|共8页
  • 作者单位

    Natl Canc Ctr Res Inst &

    Hosp Dept Urol Ctr Prostate Canc Goyang South Korea;

    Natl Canc Ctr Res Inst Div Canc Epidemiol &

    Management Biometr Res Branch Goyang South Korea;

    Natl Canc Ctr Res Inst Div Canc Epidemiol &

    Management Biometr Res Branch Goyang South Korea;

    Natl Canc Ctr Res Inst &

    Hosp Dept Urol Ctr Prostate Canc Goyang South Korea;

    Natl Canc Ctr Res Inst &

    Hosp Dept Urol Ctr Prostate Canc Goyang South Korea;

    Natl Canc Ctr Res Inst &

    Hosp Dept Urol Ctr Prostate Canc Goyang South Korea;

    Natl Canc Ctr Res Inst &

    Hosp Dept Pathol Ctr Prostate Canc Goyang South Korea;

    Natl Canc Ctr Res Inst &

    Hosp Dept Urol Ctr Prostate Canc Goyang South Korea;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 人体形态学;
  • 关键词

    Renal cell carcinoma; Comparison; Cyst; Immunohistochemistry;

    机译:肾细胞癌;比较;囊肿;免疫组化;

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号